

***Remarks***

Upon entry of the foregoing amendments, claims 1-12, 15-51, 54-59, 62-63, and 65 are pending in the application, with claims 1, 16, 49, 55, 56, and 63 being the independent claims. Claim 65 is sought to be amended by the present amendment. Claims 13-14, 52-53, 60-61, and 64 are sought to be cancelled by the present amendment without prejudice to or disclaimer of the subject matter therein.

Claim 65 has been amended to correct a typographical error by deleting the incorrectly-spelled "pharmceutical" and inserting therein the correctly-spelled "pharmaceutical."

Applicants also have amended the first page of the specification to add a statement regarding federally sponsored research, as required under 37 C.F.R. §§ 401.3 and 401.14(f)(4).

These changes are believed to introduce no new matter and their entry is respectfully requested.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Ann E. Summerfield  
Attorney for Applicants  
Registration No. 47,982

Date: February 15, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600